Fludarabine
Relapsed/Refractory
M.D. Anderson Cancer CenterSmall moleculePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
15 Active assets in the Relapsed/Refractory cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE M.D. Anderson Cancer Center | Phase 2 | B |
PAN-FGFR TYROSINE KINASE INHIBITOR JNJ-42756493 University Health Network, Toronto | Phase 2 | CCC |
Bcma Car-T Cells The First Affiliated Hospital of Xiamen University | Phase 2 | CCC |
Cytosin-Arabinosid M.D. Anderson Cancer Center | Phase 1/2 | CCC |
Pomalidomide Millennium Pharmaceuticals, Inc. | Phase 1/2 | CCC |
View all 18 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →